Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp insertion in exon 1 and Insertion of the selection cassette in exon 1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-BAG2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The BAG2 protein also known as Bcl-2-associated athanogene 2 is a co-chaperone that modulates the activity of heat shock proteins especially Hsp70. It has a molecular mass of approximately 27 kDa. BAG2 regulates the degradation of misfolded proteins by binding to the ATPase domain of Hsp70. It is expressed widely in human tissues including the brain heart and skeletal muscle suggesting its broad physiological importance.
Biological function summary
The role of BAG2 involves maintaining protein homeostasis a critical aspect of cellular functions. It forms a complex with Hsp70 assisting in the proper folding of newly synthesized proteins and preventing their aggregation. BAG2 also impacts the ubiquitin-proteasome system by blocking the association of Hsp70 with CHIP an E3 ubiquitin ligase. This regulation prevents the proteolytic degradation of client proteins.
Pathways
BAG2 functions within the cellular stress response and protein folding pathways. It has a significant involvement in the Hsp70-mediated protein folding pathway where it influences the fate of various substrate proteins. The interaction of BAG2 with Hsp70 and the ubiquitin-proteasome pathway highlights its contribution to cellular homeostasis. Additionally BAG2's modulation of these pathways suggests a link with apoptosis regulation where it associates indirectly with Bcl-2 family members.
BAG2 has been linked to neurodegenerative diseases such as Alzheimer's disease. The dysregulation of BAG2 expression and function could lead to the accumulation of misfolded proteins exacerbating neurodegeneration. BAG2 also associates with various cancers where its expression may impact tumor survival and resistance to stress. Its interaction with Hsp70 and Bcl-2 proteins plays a role in these pathologies influencing disease progression and therapeutic outcomes.
